Viking Therapeutics is trading 4.3% down now at $32.41 as broad risk-off pressure weighs on biotech and other growth-focused sectors.
- Investor caution ahead of Federal Reserve Chair Kevin Warsh’s hawkish Jackson Hole speech coincides with the decline; XBI is down 2.31%.
- No fresh company-specific announcement, earnings release, or regulatory catalyst was identified for August 28, 2026.
- Phase 3 injectable VK2735 results are not expected until late 2027 at the earliest.